DelveInsight’s “Fibrodysplasia Ossificans Progressiva (FOP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fibrodysplasia Ossificans Progressiva market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Fibrodysplasia Ossificans Progressiva drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Fibrodysplasia Ossificans Progressiva treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Fibrodysplasia Ossificans Progressiva (FOP): An Overview
Fibrodysplasia Ossificans Progressiva is a rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible.
FOP is caused by a mutation in the ACVR1 gene. This gene is involved in the growth and development of bones. The mutation allows them to grow unchecked. The gene can be inherited from one parent, but in most cases of FOP, it’s a new mutation in a person with no family history of the disease.
Fibrodysplasia Ossificans Progressiva (FOP) Market Key Facts
-
A study conducted by K. Frederick et al. titled, “Fibrodysplasia ossificans progressiva” stated that FOP is extremely rare with a worldwide prevalence of approximately one in two million. Most cases arise as a result of a spontaneous new mutation. When observed, the genetic transmission is autosomal dominant and can be inherited from either mothers or fathers.
-
According to a study by Moira et al. (2021), the prevalence of FOP is approximately 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia-Pacific region.
-
According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.
-
According to Robert et al. (2021), an estimated minimum prevalence is 0.88 per million individuals (1 in 1.14 million people) in the United States.
Fibrodysplasia Ossificans Progressiva (FOP) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Fibrodysplasia Ossificans Progressiva pipeline therapies. It also thoroughly assesses the Fibrodysplasia Ossificans Progressiva market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Fibrodysplasia Ossificans Progressiva drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Fibrodysplasia Ossificans Progressiva Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Fibrodysplasia Ossificans Progressiva epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Fibrodysplasia Ossificans Progressiva epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Fibrodysplasia Ossificans Progressiva Epidemiology, Segmented as –
-
Total Prevalent cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019–2032]
-
Gender-specific cases of Fibrodysplasia Ossificans Progressiva [2019–2032]
-
Age-specific cases of Fibrodysplasia Ossificans Progressiva [2019–2032]
-
Total Diagnosed Prevalent Cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019–2032]
Fibrodysplasia Ossificans Progressiva Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Fibrodysplasia Ossificans Progressiva market or expected to be launched during the study period. The analysis covers the Fibrodysplasia Ossificans Progressiva market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Fibrodysplasia Ossificans Progressiva drugs based on their sale and market share.
The report also covers the Fibrodysplasia Ossificans Progressiva pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Fibrodysplasia Ossificans Progressiva companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Fibrodysplasia Ossificans Progressiva Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-market
Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics Analysis
Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Fibrodysplasia Ossificans Progressiva. There are several promising drugs in the pipeline including Palovarotene (Ipsen), Garetosmab (Regeneron Pharmaceutical), and BCX9250 (Biocryst) among others. Currently, Regeneron is leading the therapeutics market with its Fibrodysplasia ossificans progressiva drug candidates in the most advanced stage of clinical development.
Fibrodysplasia Ossificans Progressiva (FOP) Companies Actively Working in the Therapeutics Market Include
-
Regeneron Pharmaceuticals
-
Ipsen
-
Incyte Corporation
-
Daiichi Sankyo
-
Blueprint Medicines
And Many Others
Emerging and Marketed Fibrodysplasia Ossificans Progressiva (FOP) Therapies Covered in the Report Include:
-
REGN2477: Regeneron
-
IPN60130: Ipsen
-
BLU-782: Blueprint Medicines
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Fibrodysplasia Ossificans Progressiva Competitive Intelligence Analysis
4. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance
5. Fibrodysplasia Ossificans Progressiva Disease Background and Overview
6. Fibrodysplasia Ossificans Progressiva Patient Journey
7. Fibrodysplasia Ossificans Progressiva Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Fibrodysplasia Ossificans Progressiva Treatment Algorithm, Current Treatment, and Medical Practices
9. Fibrodysplasia Ossificans Progressiva Unmet Needs
10. Key Endpoints of Fibrodysplasia Ossificans Progressiva Treatment
11. Fibrodysplasia Ossificans Progressiva Marketed Therapies
12. Fibrodysplasia Ossificans Progressiva Emerging Drugs and Latest Therapeutic Advances
13. Fibrodysplasia Ossificans Progressiva Seven Major Market Analysis
14. Attribute Analysis
15. Fibrodysplasia Ossificans Progressiva Market Outlook (In US, EU5, and Japan)
16. Fibrodysplasia Ossificans Progressiva Companies Active in the Market
17. Fibrodysplasia Ossificans Progressiva Access and Reimbursement Overview
18. KOL Views on the Fibrodysplasia Ossificans Progressiva Market
19. Fibrodysplasia Ossificans Progressiva Market Drivers
20. Fibrodysplasia Ossificans Progressiva Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Lymphedema Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Lymphedema market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Lymphedema market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/